Guideline for postmarketing Chinese medicine pharmacoeconomic evaluation

Xin Wang; Zhi-fei Wang; Yan-ming Xie; Wen Zhang; Xing Liao; Yan-peng Chang

doi:10.1007/s11655-014-1749-y

Your Location：

Home >

Browse articles >

Guideline for postmarketing Chinese medicine pharmacoeconomic evaluation

OriginalPaper | Updated：2021-08-27

- Guideline for postmarketing Chinese medicine pharmacoeconomic evaluation
- Guideline for postmarketing Chinese medicine pharmacoeconomic evaluation
- 中国结合医学杂志（英文版） 2015年21卷第6期页码：473-480
- Affiliations：
  
  1. Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences,Beijing,China
  2. Beijing Bionovo Medicine Development Co., Ltd.,Beijing,China
- Author bio：
- Funds：
  
  Supported by the Research on Key Techniques of Reevaluation of Postmarketing Chinese Medicines, the Ministry of Science and Technology (No. 2009ZX09502-030), the Seventh-Science Foundation of China Academy of Chinese Medical Sciences (No. ZZ070817), and National Natural Science Foundation of China (General program, No. 81202776)
- DOI：10.1007/s11655-014-1749-y
  中图分类号：
- 纸质出版日期：2015，
  
  网络出版日期：2014-3-27，
Scan for full text
Wang, X., Wang, Zf., Xie, Ym. et al. Guideline for postmarketing Chinese medicine pharmacoeconomic evaluation., Chin. J. Integr. Med. 21, 473–480 (2015). https://doi.org/10.1007/s11655-014-1749-y

Xin Wang, Zhi-fei Wang, Yan-ming Xie, et al. Guideline for postmarketing Chinese medicine pharmacoeconomic evaluation[J]. Chinese Journal of Integrative Medicine, 2015,21(6):473-480.
Wang, X., Wang, Zf., Xie, Ym. et al. Guideline for postmarketing Chinese medicine pharmacoeconomic evaluation., Chin. J. Integr. Med. 21, 473–480 (2015). https://doi.org/10.1007/s11655-014-1749-y DOI：

Xin Wang, Zhi-fei Wang, Yan-ming Xie, et al. Guideline for postmarketing Chinese medicine pharmacoeconomic evaluation[J]. Chinese Journal of Integrative Medicine, 2015,21(6):473-480. DOI： 10.1007/s11655-014-1749-y.

摘要

Pharmacoeconomics is an important part of the postmarketing Chinese medicine (CM) evaluation

and postmarketing pharmacoeconomic evaluation can reveal the clinical and market value of CM. The purpose of establishing the guideline for pharmacoeconomic evaluation is to make the evaluation process and results regarding Chinese patent medicines both scientific and fair. Every country’s guidelines for pharmacoeconomic evaluation act as reference guidelines

we have already drawn up the guideline that takes into account the special characteristics of CM; and these are in preparation for the postmarketing CM pharmacoeconomic evaluation.

Abstract

Pharmacoeconomics is an important part of the postmarketing Chinese medicine (CM) evaluation

we have already drawn up the guideline that takes into account the special characteristics of CM; and these are in preparation for the postmarketing CM pharmacoeconomic evaluation.

关键词

postmarketing evaluationChinese Medicinepharmacoeconomicsguideline

Keywords

postmarketing evaluationChinese Medicinepharmacoeconomicsguideline

references

Zhang W, Xie YM, Yuwen Y. Exploration of how to formulate guidelines on post-marketing traditional Chinese medicine surveillance. China J Chin Mater Med (Chin) 2013;38:2943–2948.

Research Group of Pharmacoeconomics Evaluation of China. Guide to pharmacoeconomics evaluation of China (revision 2011). China J Pharm Econom (Chin) 2011;3:6–48.

FMCP Format Executive Committee. The AMCP format for formulary submissions (version 3.0). J Manag Care Pharm 2010;16:1–30.

Guidelines for pharmacoeconomic research, updated version. Diemen: College voor zorgverzekeringen; 2006.

Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (version 4.3). Canberra (ACT): Australian Government Department of Health and Ageing.

Chen W, Hu SL. Put up a platform of pharmacoeconomics study and practice. J China Prescr Drug (Chin) 2008;4:12–15.

Tian F, Fu YK, Xie YM. Probe on the estimate methods of sample size for postmarketing clinical evaluation of Chinese medicine. China J Chin Mater Med (Chin) 2011;36:1097–1102.

Yang L, Hu SL. Cost accounting of pharmacoeconomics evaluation, pharmacoeconomics research and evaluation centre. [EB/OL]. [2007-03-05]. http://sph.fudan.edu.cn:81/per/paper.shtmlcmd=uv&scope=pe&lan=zh&id=4028803b1 11d772801111d8982990006.

Yang L, Hu SL. Cost definition in pharmacoeconomics evaluation and existing controversy. Chin Pharm (Chin) 2003;14:670–672.

Yang L, Hu SL, Chen W. Comparison of daily estmate method of five confidence intervals of cost-effectiveness ratios. Chin J Health Stat (Chin) 2004;21:150–153.

Zhang F, Wang M, Du J. The research development of pharmacoeconomic evaluation on Chinese medicine. China J Pharm Econom (Chin) 2009;5:44–50.

FULL TEXT LINK

More>

浏览量

153

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

Herb-Induced Liver Injury: A Global Concern

Guidelines for the Diagnosis and Management of Herb-Induced Liver Injury

Future view and development of immunology: Exploring the immunology based on Chinese medicine and culture

Cost-effectiveness analysis of combined Chinese medicine and Western medicine for ischemic stroke patients

Objective tongue inspection on 142 liver cancer patients with damp-heat syndrome